Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyESMO Open 2021 Oct 01;6(5)100241, R de Wit, C Wülfing, D Castellano, G Kramer, JC Eymard, CN Sternberg, K Fizazi, B Tombal, A Bamias, J Carles, R Iacovelli, B Melichar, Á Sverrisdóttir, C Theodore, S Feyerabend, C Helissey, MC Foster, A Ozatilgan, C Geffriaud-Ricouard, J de Bono
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.